TherapeuticsMD Announces Third Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
TherapeuticsMD (TXMD) Misses Q3 EPS by 2c
November 3, 2016 4:31 PM EDTTherapeuticsMD (NYSE: TXMD) reported Q3 EPS of ($0.13), $0.02 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $5.53 million versus the consensus estimate of $5.76 million.
We are making excellent progress this year advancing our pipeline and enhancing our commercial capabilities... More
